Recontact practices of cancer genetic counselors and an exploration of professional, legal, and ethical duty.

cancer clinical genetics ethics genetic counseling genetic testing genetics law medical ethics multi-gene panel professional duty professional issues recontact

Journal

Journal of genetic counseling
ISSN: 1573-3599
Titre abrégé: J Genet Couns
Pays: United States
ID NLM: 9206865

Informations de publication

Date de publication:
08 2019
Historique:
received: 27 04 2018
revised: 15 03 2019
accepted: 17 03 2019
pubmed: 7 5 2019
medline: 7 7 2020
entrez: 7 5 2019
Statut: ppublish

Résumé

The duty to recontact continues to be revisited in the field of clinical genetics and is currently relevant for cancer genetic counseling given the transition from single-gene to multi-gene panel testing. We recruited cancer genetic counselors through the National Society of Genetic Counselors list-serv to complete an online survey assessing current practices and perspectives regarding recontacting patients about diagnostic genetic tests. Forty-one percent of respondents reported that they have recontacted patients to offer updated (new) diagnostic genetic testing (40/97). A majority (61%, 17/28), of genetic counselors who reported recontact specifically for panel testing indicated that the availability of management recommendations for genes not previously tested routinely was an important factor in the decision to recontact. All respondents who recontacted patients reported "improved patient care" as a perceived benefit. Respondents indicated that recontact is mostly a patient responsibility (49%), followed by a shared responsibility between the provider and patient (43%). Few respondents (2%) reported a uniform ethical duty to recontact patients regarding new and updated testing, while the majority (89%) felt that there was some degree of ethical duty. A greater percentage of those who reported past recontact practices reported intention to recontact in the future (p = 0.001). There is little consensus among the genetic counselor respondents about how to approach the recontacting of patients to offer updated genetic testing.

Identifiants

pubmed: 31058402
doi: 10.1002/jgc4.1126
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-846

Informations de copyright

© 2019 National Society of Genetic Counselors.

Auteurs

Amy Mueller (A)

Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, Massachusetts.
MS Genetic Counseling Program, Boston University School of Medicine, Boston, Massachusetts.

Emily Dalton (E)

Ambry Genetics, Aliso Viejo, California.

Danielle Enserro (D)

Boston University School of Public Health, Boston, Massachusetts.

Catharine Wang (C)

Boston University School of Public Health, Boston, Massachusetts.

Maureen Flynn (M)

MGH Institute of Health Professions, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH